BioMarin Pharmaceutical (BMRN) reported Q1 non-GAAP earnings late Thursday of $1.13 per diluted share, up from $0.71 a year earlier.

Analysts polled by FactSet expected $0.95.

Revenue in the three months ended March 31 rose to $745.1 million from $648.8 million a year earlier.

Analysts surveyed by FactSet expected $738.7 million.

The company reiterated 2025 non-GAAP diluted EPS guidance of $4.20 to $4.40, on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet expect EPS of $4.30 on revenue of $3.14 billion.

Shares of BioMarin rose 1.1% in after-hours trading.